Ameriprise’s Revelation Biosciences Warrant REVBW Stock Holding History

Ameriprise’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,886	Closed	-$16K	–	4011
2021 Q4	$16K	Buy	+22,886	New	+$14K	﹤0.01%	3930

Other funds holding REVBW

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ameriprise's REVBW Position: Q1 2022 in Review

Ameriprise sold out of Revelation Biosciences Warrant (REVBW) in Q1 2022, closing a stake of 22,886 shares — an estimated $16K sold.

Ameriprise first reported a position in REVBW in Q4 2021 and held it in 1 quarter. The position peaked at $16K in Q4 2021. 18 funds tracked by Wall St. Rank hold REVBW as of Q1 2022.

Ameriprise reported no remaining Revelation Biosciences Warrant position as of Q1 2022 after selling out during the quarter.
Ameriprise sold 22,886 Revelation Biosciences Warrant shares in Q1 2022, an estimated $16K.
Ameriprise first reported a position in Revelation Biosciences Warrant in Q4 2021 and held it in 1 quarter.
Ameriprise's Revelation Biosciences Warrant position peaked at $16K in Q4 2021.
18 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q1 2022.

Based on Ameriprise's 13F filing for Q1 2022, filed 16 May 2022.